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INTRODUCTION
Nasal-type extranodal natural killer (NK)/T-cell lymphoma 
(ENKTL), formerly referred to as polymorphic reticulosis, mid-
line malignant reticulosis, or T-cell angiocentric lymphoma, 
was classified as NK/T-cell lymphoma in the 1998 World Health 
Organization (WHO) classification. According to a nationwide 
study of malignant lymphomas, ENKTL is the third most com-
mon lymphoma in Korea.1 Early-stage ENKTL, characterized 
by extensive angioinvasion and necrosis, is usually localized to 
the upper aerodigestive tract and has been associated with Ep-
stein-Barr virus infection.
The optimal management of ENKTL has changed continu-
ously. Before it was classified as a lymphoma, ENKTL was treat-
ed using radiotherapy (RT) alone. In a report from our institu-
tion,2 patients treated with RT alone experienced an 83.7% 
overall response rate, but local and systemic failure rates of 50% 
and 25%, respectively, resulting in a 5-year overall survival (OS) 
rate of 40%. After being classified as a lymphoma, upfront che-
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Materials and Methods: Fifty-five patients with stage I or II ENKTL [n=39 (71%) and 16 (29%) patients, respectively] who were 
treated with RT between 1999 and 2013 were analyzed retrospectively. The median age was 54 years (range, 24–81). Patients were 
grouped by treatment modality as RT alone [n=19 (35%)], upfront CT plus RT [CT+RT, n=16 (29%)], and concurrent chemoradio-
therapy [CCRT, n=20 (36%)]. The median RT dose was 48 Gy. Patient characteristics between each treatment group were well bal-
anced. Patterns of failure and survival were analyzed.
Results: The overall response rate after RT was 94.6%. Ten patients experienced distant failure, and seven experienced local fail-
ure comprising five in-field and two out-field failures. The local and distant failure rates in the RT-alone group were the same 
(16%). In the CT+RT group, the most common failure sites were local (19%). In the CCRT group, the most common failures were 
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motherapy (CT) was administered as the first-line treatment, 
although frequent local failures were observed.3 Although com-
binations of multiple CT agents such as cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP); etoposide, 
prednisone, vincristine, cyclophosphamide, and doxorubicin 
(EPOCH); and steroid, methotrexate, ifosfamide, L-asparagi-
nase, and etoposide (SMILE), were used with concurrent (CCRT) 
or sequential chemoradiotherapy (CT+RT), neither the inci-
dence of systemic relapse nor the prognosis were significantly 
altered by the inclusion of CT.4 Furthermore, the local control 
rates with CT combinations were comparable to those for RT 
alone when using modern radiation techniques.4 CCRT fol-
lowed by maintenance CT was considered as a treatment op-
tion. According to the Korean lymphoma consortium,5 CCRT 
followed by VP-16, ifosfamide, cisplatin, and dexamethasone 
(VIPD) showed promising outcomes, resulting in a 73% com-
plete response (CR) rate and a 3-year OS rate of 86.2%. None-
theless, distant failures did not decrease compared to data for 
RT alone.
There is no clear consensus on the optimal management for 
ENKTL, and randomized trials comparing RT alone with CCRT 
have not been conducted. Presently, the National Comprehen-
sive Cancer Network guidelines recommend RT alone, CCRT, 
or CT+RT for stage I ENKTL without any known risk factors. 
This study analyzed clinical outcomes including the failure pat-
terns, survival, and toxicities in patients with stage I and II EN-
KTL to further evaluate and compare the clinical benefits of RT 
and CT for the treatment of ENKTL.
MATERIALS AND METHODS
Patients
Between 1999 and 2013, 82 patients with ENKTL underwent RT 
at Yonsei Cancer Center in Seoul, Korea. After reviewing the pa-
thology and medical records retrospectively, 17 patients with 
Ann Arbor stage III or IV disease and eight patients with prima-
ry tumors in regions other than the head and neck region were 
excluded. In addition, two patients were excluded as they had 
undergone salvage therapy after first-line treatment failure. The 
final analysis population consisted of 55 eligible patients with 
stage I or II ENKTL.
A pathologic diagnosis of ENKTL was based on either atypi-
cal CD56-expressing lymphoid cell proliferation or nuclear Ep-
stein-Barr virus–encoded small mRNA-positive and cytoplas-
mic cytotoxic molecule–expressing atypical lymphoid cell 
proliferation. At diagnosis, patients underwent pretreatment 
evaluations including history taking, physical examination, 
complete blood count, serum biochemistry analysis including 
lactate dehydrogenase (LDH) level measurements, bone mar-
row aspiration and biopsy, computed tomography scanning 
and/or magnetic resonance imaging (MRI) of the involved le-
sion, and positron emission tomography (PET). PET was per-
formed in 41 patients (74.5%).
Patient characteristics are summarized in Table 1. The medi-
an age was 54 years (range, 24–81 years). Seventeen patients 
(68%) were younger than 60 years of age. The male/female ratio 
was 1.6:1. According to the NK/T-cell lymphoma prognostic in-
dex (NKPI),6 which includes the presence of “B” symptoms, le-
sions at stages III or IV, elevated serum LDH concentration, and 
lymph node involvement, 15 patients (28%) were classified as 
group III or IV (i.e., those with >2 risk factors).
Patients were subdivided into groups based on the treatment 
modality as follows: RT alone (n=19, 35%), CT+RT (n=16, 29%), 
and CCRT (n=20, 36%). Before 1987, our treatment policy for 
stage I or II ENKTL was to administer involved-field RT alone. 
After 1987, patients underwent either CT+RT or RT alone. More 
recently, patients have been treated with CCRT alone or CCRT 
followed by maintenance CT. Patients’ characteristics between 
the groups were well balanced and are shown in Table 2.
Treatments
In the CT+RT group, fifteen of 16 patients received mainte-
nance CT after RT. Seven patients were administered CHOP; 
five were administered cyclophosphamide, vincristine, VP-16, 
Table 1. Patient Characteristics
Variables Groups n %
Sex Male 34 62
Female 21 38
Age (yrs) Median (range) 54 (24–81)
≥60 17 32
<60 38 68
Ann Arbor stage I 39 71
II 16 29
Performance status ECOG 0, 1 52 94
ECOG 2 3 6
Primary site Sinonasal 47 86
Others 8 14
Epstein-Barr virus Yes 13 24
Not checked 42 76
Serum LDH Elevated 26 68
Normal 12 32
B symptoms Yes 13 24
No 42 76
IPI 1 (low) 21 38
2 (low intermediate) 28 51
3 (high-intermediate) 6 11
4 (high) 0 0
NKPI Group 1 19 35
Group 2 21 38
Group 3 13 24
Group 4 2 4
ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic in-
dex; LDH, lactate dehydrogenase; NKPI, NK/T cell lymphoma prognostic in-
dex.6
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doxorubicin, and prednisone; and four were administered ifos-
famide, methotrexate, and VP-16 (IMVP-16). Twenty patients 
(53%) had cisplatin-based CCRT, 15 of whom were treated with 
maintenance CT, mainly consisting of VIPD. 
Contrast-enhanced computed tomography simulation using 
a thermoplastic device was mandatory. A mouthpiece was 
used to distance the tongue from the radiation field in patients 
who underwent nasal cavity irradiation. All patients underwent 
involved-site RT (ISRT).7,8 Limited-field ISRT included all gross 
lesions and adequate margins. Extended-field ISRT included 
all gross lesions, the bilateral nasal cavities, and the paranasal 
sinus in cases of stage I disease, and all gross lesions, the bilat-
eral nasal cavities, the paranasal sinus, and the side of involved 
cervical lymph nodes in cases of stage II disease. In patients 
with gross lesions outside the nasal cavity, the target volume of 
extended-field ISRT included the gross lesions, Waldeyer’s ring, 
and the bilateral cervical lymph nodes. Ten patients (18%) un-
derwent two-dimensional RT, 35 (64%) underwent three-di-
mensional conformal RT (3D-CRT) using 6 MV photons gener-
ated by a linear accelerator, and ten (18%) underwent intensity-
modulated RT (IMRT) using tomotherapy. Target volume was 
determined according to the International Commission on Ra-
diation Units and Measurements Report 83.9 We prescribed the 
radiation dose based on the dose to 95% of the considered vol-
ume (D95). Using 3D-CRT, the most common field arrange-
ment was the three-field technique consisting of arrangements 
weighted in favor of the anterior field and two wedged lateral 
fields. After a total dose of 45 Gy was irradiated to the gross tu-
mor, a boost dose in the range of 9–18 Gy (up to a total dose of 
54–63 Gy) was administered for persistent tumors.
Using IMRT, the simultaneously integrated boost technique 
was used. Clinical target volume (CTV)1 encompassed the 
gross lesion, and CTV2 encompassed the margins of CTV1; 
these were different for the limited and extended-field ISRT. 
The CTV was modified to reduce the dose to organs at risk. The 
maximal dose constraints to the spinal cord, optic apparatus, 
and mandible were <45 Gy, <55 Gy, and <70 Gy, respectively. 
The larynx, pharynx, and esophagus were also delineated, and 
the doses were set as low as possible. For the planning target 
volume, a 0.3 cm margin was applied to the CTV. Two different 
dose prescriptions were used. For a 20-fraction prescription, 
the total doses applied to the CTV1 and CTV2 were 48 and 40 
Gy, respectively. For a 25-fraction prescription, the total doses 
applied to the CTV1 and CTV2 were 53 and 45 Gy, respectively.
The radiation doses ranged from 22 to 63 Gy (median, 48 Gy) 
at a dose per fraction of 1.8–2.4 Gy within 4–6 weeks. Forty-two 
patients (76%) received >45 Gy. Assuming an α/β ratio of 10 Gy, 
24 patients (43.6%) received 40–45 Gy, 20 patients (36.4%) re-
ceived 46–50.4 Gy, and nine patients (16.4%) received 54–63 Gy 
in a 1.8 Gy–equivalent dose. Two patients (3.6%) received <40 
Gy. A 68-year-old male, who underwent cisplatin-based CCRT, 
died from pneumonia exacerbation after 22 Gy. A 50-year-old 
male, who underwent CT+RT consisting of IMVP-16, refused 
RT after 23.4 Gy due to grade IV oral mucositis.
Table 2. Patient Characteristics According to Treatment Modality Groups
Variables Groups RT alone, n (%) CT+RT, n (%) CCRT, n (%) p value
Sex Male 10 (53) 12 (75) 12 (60) 0.395
Female 9 (47) 4 (25) 8 (40)
Age (yrs) ≥60 12 (63) 14 (88) 12 (60) 0.169
<60 7 (37) 2 (12) 8 (40)
Stage I 15 (79) 11 (69) 13 (65) 0.656
II 4 (21) 5 (31) 7 (35)
Performance ECOG 0, 1 19 (100) 16 (100) 17 (85) 0.102
ECOG 2 0 (0) 0 (0) 3 (15)
Primary site Sinonasal 15 (79) 13 (81) 19 (95) 0.352
Others 4 (21) 3 (19) 1 (5)
Serum LDH Elevated 5 (71) 9 (82) 12 (60) 0.476
Normal 2 (29) 2 (18) 8 (40)
B symptoms Yes 3 (16) 3 (19) 7 (35) 0.376
No 16 (84) 13 (81) 13 (65)
IPI 1 10 (53) 7 (44) 4 (20) 0.225
2 8 (42) 8 (50) 12 (60)
3 1 (5) 1 (6) 4 (20)
NKPI Group 1 10 (53) 5 (31) 4 (20) 0.302
Group 2 7 (37) 6 (38) 8 (40)
Group 3 2 (11) 4 (25) 7 (35)
Group 4 0 (0) 1 (6) 1 (5)
RT, radiotherapy; CT, chemotherapy; CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; LDH, 
lactate dehydrogenase; NKPI, NK/T cell lymphoma prognostic index.6
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Assessment and evaluation
Treatment response was assessed according to the WHO criteria. 
A CR was defined as the disappearance of all previously measur-
able lesions and the absence of any new tumor lesions. A partial 
response (PR) was defined as a decrease of ≥50% in the product 
of two perpendicular diameters of each measurable lesion. Sta-
ble disease was defined as a decrease of <50% or an increase of 
<25% in tumor size. Progressive disease (PD) was defined as a 
≥25% increase in the product of the two diameters of at least one 
tumor or as the presence of any newly developed lesion.
Treatment failure was categorized as local failure, regional 
failure, or distant failure. Distant failure was diagnosed based 
on the clinical and/or radiologic findings and was defined as 
the appearance of systemic disease at sites other than the head 
and neck or cervical neck lymph nodes. Local failure was cate-
gorized as proposed by Koom, et al.10 into true recurrence (TR) 
that occurred within RT fields, marginal recurrence that oc-
curred near contiguous areas of the primary site yet just outside 
the border of the RT field, and elsewhere recurrence (ER) that 
occurred at other extranodal sites in the head and neck. Re-
gional failure was defined as any recurrence in the cervical 
neck nodes.
To monitor disease progression and patterns of failure, evalu-
ations were performed 1 month after treatment and every 3–6 
months thereafter. RT response was assessed via physical ex-
amination (n=4, 7%), computed tomography (n=35, 64%), MRI 
(n=5, 9%), and PET (n=10, 18%). PET was performed for recent 
patients. Response evaluation was performed within 3 months 
after the completion of RT for all patients and at 1 month for 
patients who received CCRT. Treatment-related toxicities were 
assessed at every follow-up visit. Toxicities were graded based 
on the Common Toxicity Criteria Version 4.0 from the National 
Cancer Institute (NCI-CTC v4.0).
Statistical analyses
All statistical analyses were conducted using SPSS version 20.0 
(SPSS Inc., Chicago, IL, USA). OS, progression-free survival 
(PFS), and local failure-free survival (LFFS) were determined 
using the Kaplan-Meier method, and the differences were eval-
uated using the log-rank test. Survival time was measured from 
the date of diagnosis to the date of death from any cause or the 
date of last follow-up. PFS was an estimation of the measure-
ment from the date of diagnosis to the date of initial relapse or 
death. LFFS was an estimation of the measurement from the 
date of diagnosis to the date of local failure or death. A p-value 
of <0.05 was considered to be statistically significant.
RESULTS
Response to RT and patterns of treatment failure
The RT response and treatment outcomes are summarized in 
Fig. 1. Forty-two patients (76.4%) achieved a CR, and ten (18.2%) 
achieved a PR. Three patients (5.4%) did not complete the RT 
and/or died from PD during or immediately after RT.
Nineteen patients experienced treatment failure (Fig. 2). Two 
patients had multiple failure sites and 17 had a single failure 
site. The most common failure was distant failure occurring in 
ten patients (eight had skin metastasis, one had lung metasta-
sis, and one had para-aortic lymph node metastasis). Four pa-
tients (7%) experienced regional failure: three had stage I dis-
ease and one had stage II disease. Except for two patients who 
had primary tumors of the tonsil area, 37 patients with stage I 
disease received extended-field ISRT, and 3 of the 37 patients 
(8%) experienced untreated regional node failure. Of the 16 pa-
tients with stage II disease, 14 who received bilateral neck node 
irradiation did not experience regional failure. However, one of 
two patients (50%) who received involved neck node irradia-
Fig. 1. Summary of treatment outcomes and treatment failures. RT, radio-
therapy; CR, complete response; PR, partial response; UE, unevaluable; 
CT, chemotherapy; SD, stable disease; PD, progressive disease; NED, no 
evidence of disease; TRD, treatment-related death; DOC, death due to 
other cause; DOD, death due to disease; CCRT, concurrent chemoradio-
therapy.
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tion experienced untreated regional node failure.
The characteristics of seven patients (11%) who experienced 
local failure, comprising TR in five patients and ER in two pa-
tients, are summarized in Table 3. Five patients had stage I dis-
ease, and two patients had stage II disease. Three patients re-
ceived upfront CT followed by RT, three patients received RT 
alone, and one patient received CCRT. Six patients received less 
than 50 Gy, mostly 45 Gy in 25 fx. Six of seven patients were suc-
cessively salvaged, and they survived for a long period of time. 
Three patients were salvaged with re-irradiation (Patients 4, 6, 
and 7), two patients with CT (Patients 2 and 5), and one patient 
(Patient 1) with CT and RT. Initial RT dose/re-irradiation dose 
were 50.4/40, 45/34.8, and 45/44 Gy, respectively. We pre-
scribed relatively lower doses due to the possibility of radiation 
toxicity; however, the results of re-irradiation were successful, 
and radiation toxicity did not occur. One patient (Patient 2) who 
was initially treated with cisplatin-based CCRT was salvaged 
with IMVP-16, and the other patient (Patient 5) who was initial-
ly treated with IMVP-16 and RT was salvaged with EPOCH. One 
patient (Patient 1) who was initially treated with IMVP-16 and 
RT was salvaged with EPOCH and re-irradiation of 41.4 Gy.
Patterns of failure according to treatment modality are shown 
in Table 4. For the RT-alone group, local and distant failure oc-
curred at the same frequency. For the CT+RT group, local fail-
ure was most common. For the CCRT group, distant failure was 
most common.
Survival analysis and prognostic factors
The median follow-up time was 26 months (range, 1–178 
months) for all patients and 56 months (range, 1–178 months) 
for patients who were alive at the time of the analysis.
The median follow-up times for surviving patients of the RT-
alone, CT+RT, and CCRT groups were 73 months (range, 1–178 
months), 64.5 months (range, 3–133 months), and 38.5 months 
(range, 6–86 months), respectively. The 5-year OS and PFS rates 
for all 55 patients were 66% and 54%, respectively. The 5-year 
OS rate for the RT-alone, CT+RT, and CCRT groups were 76%, 
69%, and 55%, respectively (p=0.388). The 5-year PFS rates for 
the RT-alone, CT+RT, and CCRT groups were 70%, 47%, and 
48%, respectively (p=0.48). The 5-year LFFS rates for the RT-
alone, CT+RT, and CCRT groups were 93%, 69%, and 100%, re-
spectively (p=0.338) (Fig. 3).
The clinical and treatment factors assessed for potential 
prognostic impact are shown in Table 5. Among these, achiev-
ing a CR after RT was the only statistically significant prognostic 
factor affecting 5-year OS. Patients classified as IPI group 3 
(high-intermediate) or NKPI group 4 showed a trend toward 
worse 5-year OS rates than those of other groups, although the 
differences were not statistically significant (p=0.052 and 0.434, 
respectively).
Toxicity
Radiation-induced toxicities were minimal. Grade 1 or 2 muco-
sitis was observed in 17 patients [31%; RT alone (2 patients), 
CT+RT (3), and CCRT (12)]. Grade 1 or 2 nausea or vomiting 
was observed in 13 patients [24%; RT alone (1 patient), CT+RT 
(3), and CCRT (9)]. However, a 50-year-old male patient in the 
CT+RT group experienced grade 4 oral mucositis during RT 
and withdrew from RT treatment.
Hematologic toxicities occurred during CCRT or mainte-
nance CT. Of 36 patients who received CT, grade 1 or 2 leukope-
nia was observed in eight patients [22%; CT+RT (1 patient), 
CCRT (7)], and grade 3 or 4 leukopenia or thrombocytopenia 
was observed in four patients (11%) in the CCRT group. There 
were five treatment-related deaths [CT+RT (1 patient), CCRT 
(4)]. During maintenance CT, one patient in the CT+RT group 
died from gram-positive sepsis, whereas four patients in the 
CCRT group died from neutropenic fever and pneumonia ag-
gravation.
DISCUSSION
Several studies have shown that RT alone produces a good CR 
rate in patients with early-stage ENKTL; however, frequent dis-
tant and local failures within 2 years of RT completion have 
been a major obstacle to successful treatment.2,10 Subsequent 
studies showed that ENKTL responded poorly to anthracy-
cline-based chemotherapies, and patients exhibited frequent 
local failure and disease progression,11,12 which was thought to 
be due to the expression of a multidrug-resistant P-glycoprotein 
in ENKTL.13 With the application of dose-intensified upfront 
CT, the CR rate improved, although the 3-year OS and distant 
failure rates did not improve.14 Therefore, trials of CCRT that 
used CT as a radiosensitizer were designed.5,15 Although doses 
of >50 Gy were suggested in an RT alone setting,10 lower doses 
were recommended during CCRT to reduce potential toxicities. 
Despite these advancing treatment paradigms, there have 
been no conclusive studies comparing RT alone with CCRT.
This study evaluated the role of RT and CT for the treatment 
Fig. 2. Patterns of failure.
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of ENKTL. The study cohort reflected the changing treatment 
paradigms over time. The RT-alone group was mostly treated 
between 1999 and 2004, the RT+CT group between 2002 and 
2006, and the CCRT group between 2007 and 2013. Although 
the present study contained potential biases associated with 
the retrospective analysis of patients treated without a consis-
tent protocol, the results contained herein showed a remark-
able improvement in treatment outcomes compared with his-
torical data for RT alone. We previously reported that 50% of 
patients treated with RT alone experienced local failure and 
that the 5-year OS rate was 40%.2,10 However, more recently, Li, 
et al.16 showed that only 5% of patients treated with RT alone 
experienced local failure and that the 5-year OS rate was 80%, 
findings of which are congruent with those in the present study. 
Here, the local failure rate of RT alone was 16% and the 5-year 
OS rate was 76%.
Improvements in the outcome of RT alone are likely due to 
the development of imaging modalities that have enabled a 
more complete determination of disease extent for treatment 
planning. IMRT and image-guided radiotherapy (IGRT) have 
been used recently in almost all cases involving the head and 
neck area, and most patients with ENKTL underwent limited or 
extended-field ISRT.16-19 ISRT is newly defined concept pro-
posed by the International Lymphoma Radiation Oncology 
Group. ISRT encompasses the involved sites of disease based 
on detectable nodal and extranodal extension involvement us-
ing imaging modalities, which results in relatively smaller vol-
umes than the larger, nodal station–derived volumes of previ-
ous extended-field and involved-field RT. In ENKTL, the volume 
of ISRT is similar to that of involved-field RT. In the present 
study, all patients underwent extended-field ISRT, and the ma-
jority of patients underwent IGRT with 3D-CRT (64%) or IMRT 
(16%). In addition, to determine tumor extent accurately, diag-
nostic MRI was fused with simulation-computed tomography.
Using these modern RT techniques and advanced imaging 
modalities resulted in, across the whole study cohort, seven pa-
tients (11%) experiencing local failure during follow-up and 
only one of these patients experiencing local failure after CCRT. 
However, the median follow-up period after CCRT was shorter 
than that of RT alone or CT+RT; therefore, a longer-term follow-
up is needed to validate whether CCRT reduces local failure 
more than RT alone or CT+RT.
A detailed review of patients who experienced local failure 
after RT provides clues concerning the determination of the op-
timal RT dose and field. In the patients who experienced local 
failure, both TRs and ERs were noted. Of the four patients who 
experienced TRs, three received a dose of <50 Gy (Patients 2, 3, 
and 6). As previously reported,10 RT should be used with a tu-
mor dose of ≥50 Gy to intensify local treatment. Despite treating 
two of these patients (Patients 2 and 3) with CT, the RT dose of 
<50 Gy appeared to be insufficient, although the addition of CT 
with the lower-dose RT might explain the later recurrences in 
Patients 2 and 3 (81 and 31 months, respectively) compared Ta
bl
e 
3. 
De
ta
ils
 o
f P
at
ie
nt
s W
ho
 E
xp
er
ie
nc
ed
 Lo
ca
l F
ai
lu
re
#
Ag
e
Se
x
St
ag
e
Pr
im
ar
y 
si
te
Tr
ea
tm
en
t g
ro
up
RT
 d
os
e
Fa
ilu
re
 s
ite
Ti
m
e 
to
 fa
ilu
re
Sa
lv
ag
e 
tre
at
m
en
t
Cu
rr
en
t s
ta
tu
s
1
52
M
IA
Rt
. n
as
al
 ca
vit
y
CT
+R
T
45
 G
y/
25
 fx
Rt
. m
an
di
bl
e 
(E
R)
6 
m
on
th
s
CT
, r
eR
T 
(4
1.
4 
Gy
)
NE
D 
11
2 
m
on
th
s
2
52
F
IA
Lt
. n
as
al
 ca
vit
y
CC
RT
44
 G
y/
20
 fx
Rt
. n
as
al
 ca
vit
y (
TR
)
81
 m
on
th
s
CT
NE
D 
87
 m
on
th
s
3
44
F
IA
Rt
. n
as
al
 ca
vit
y
CT
+R
T
45
 G
y/
25
 fx
Rt
. n
as
al
 ca
vit
y (
TR
)
33
 m
on
th
s
CT
DO
D 
88
 m
on
th
s 
   
w
ith
 re
gi
on
al
,  
   
di
st
an
t f
ai
lu
re
s
4
36
F
IA
Rt
. n
as
al
 ca
vit
y
RT
 a
lo
ne
50
.4
 G
y/
28
 fx
Rt
. n
as
al
 ca
vit
y (
TR
)
65
 m
on
th
s
re
RT
 (4
0 
Gy
)
NE
D 
13
3 
m
on
th
s
5
46
M
IIA
Na
so
ph
ar
yn
x
CT
+R
T
45
 G
y/
25
 fx
Lt
. n
as
al
 ca
vit
y (
ER
)
9 
m
on
th
s
CT
NE
D 
98
 m
on
th
s
6
54
M
IIA
Or
op
ha
ry
nx
RT
 a
lo
ne
45
 G
y/
25
 fx
Or
op
ha
ry
nx
 (T
R)
7 
m
on
th
s
re
RT
 (3
4.
8 
Gy
)
NE
D 
17
8 
m
on
th
s
7
74
F
IA
Rt
. n
as
al
 ca
vit
y
RT
 a
lo
ne
45
 G
y/
25
 fx
Lt
. n
as
al
 ca
vit
y (
ER
)
14
9 
m
on
th
s
RT
 (4
4 
Gy
)
NE
D 
15
9 
m
on
th
s
CT
, c
he
m
ot
he
ra
py
; R
T, 
ra
di
ot
he
ra
py
; C
CR
T, 
co
nc
ur
re
nt
 ch
em
or
ad
io
th
er
ap
y; 
ER
, e
lse
w
he
re
 re
cu
rre
nc
e;
 fx
, f
ra
ct
io
ns
; r
eR
T, 
re
-ra
di
ot
he
ra
py
; N
ED
, n
o 
ev
id
en
ce
 o
f d
ise
as
e;
 T
R,
 tr
ue
 re
cu
rre
nc
e;
 D
OD
, d
ea
d 
of
 d
ise
as
e.
http://dx.doi.org/10.3349/ymj.2016.57.4.846852
Radiotherapy for Early-Stage ENKTL
with that in Patient 6 (7 months). In the patient who received a 
dose of >50 Gy (Patient 4), the recurrence occurred relatively 
late (65 months), suggesting that higher-dose irradiation would 
be preferable. One patient (Patient 5) with primary disease at 
the nasopharynx experienced failure at the left nasal cavity, this 
patient was treated with CT+RT before the introduction of 
IMRT; thus, the radiation field encompassed only the pharynx 
and bilateral cervical lymph nodes yet not the nasal cavity, sug-
gesting insufficient field coverage. One patient who had prima-
ry disease at the right nasal cavity (Patient 1) experienced fail-
ure at the right mandible, and one patient who had primary 
disease at the right nasal cavity (Patient 7) experienced failure 
at the left nasal cavity. The radiation fields in both of these pa-
tients were tightly defined in order to protect the organs at risk 
(both eyes and lenses). These cases of ER implied that extend-
ed-field ISRT with generous margins is needed to control early-
Fig. 3. Overall survival (OS) (A), progression-free survival (PFS) (B), and local failure-free survival (LFFS) (C). RT, radiotherapy; CT, chemotherapy; CCRT, 
concurrent chemoradiotherapy.
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stage ENKTL. However, our experience does not justify the 
need for prophylactic irradiation of uninvolved sites, and we 
did not accumulate enough evidence concerning the optimal 
radiation volume.
Salvage treatment after local failure was successful. Either a 
CT regimen different from that initially used or re-irradiation 
could be an option for salvage treatment for recurrent disease. 
We prescribed a relatively lower dose (<50 Gy) due to the possi-
bility of radiation toxicity, and no radiation toxicity occurred. 
CT was also effective for locally recurrent disease; however, it 
was associated with considerable toxicities and required a lon-
ger treatment time. Using modern RT techniques such as IMRT 
and IGRT with advanced imaging modalities, salvage treatment 
with re-irradiation could be considered in cases of the local re-
current disease without distant failure.
In the present study, distant failure remained a dominant 
pattern of failure, despite the incorporation of CT. Wang, et al.20 
reported on CT+RT consisting of gemcitabine, oxaliplatin, and 
L-asparaginase followed by involved-field RT, and the overall 
response rate was 96.3%, with 11% of patients experiencing dis-
tant failure. In addition, the Korean Lymphoma Consortium 
published the results of CCRT for early-stage ENKTL,5 consist-
ing of weekly cisplatin-based CCRT followed by maintenance 
VIPD CT. The results were outstanding, showing an 83.3% over-
all response rate, an 85% 3-year OS rate, an 86% 3-year PFS rate, 
and a 10% distant failure rate. However, the grade IV toxicities 
rate was 41% during maintenance CT, and the short follow-up 
period provoked much controversy. In another study, the Kore-
an Lymphoma Consortium published data concerning CCRT 
followed by L-asparaginase-containing maintenance CT,15 
which demonstrated a 90% overall response rate, a 73% 5-year 
PFS rate, and a 60% 5-year OS rate with manageable toxicities. 
The Japan Clinical Oncology Group published a study of CCRT 
consisting of 50 Gy of RT with concurrent dexamethasone, eto-
poside, ifosfamide, and carboplatin CT,21 for which the overall 
response rate was 81% and the 2-year OS rate was 78%; howev-
er, the distant failure rate was 33% and not reduced by the addi-
tion of CT. In the present study, the overall distant failure rate 
was 18%, which was superior to the majority of the above stud-
ies for RT alone, CT+RT, and CCRT, yet remains high. A PET 
scan was performed in the majority of our patients, which 
might explain the lower distant failure rate observed.
High-risk factors for distant failure have not been deter-
mined. However, elevated expression of cyclooxygenase-2 was 
identified recently as a predictive factor for higher distant fail-
ure rates in an immunohistochemistry-based evaluation.22 EN-
KTL is generally very aggressive, and if left untreated it is uni-
formly fatal. Several investigators have classified ENKTL into 
two subgroups: nasal and extra-nasal/nasal-type, the former 
being characterized by locoregional aggressiveness, and the lat-
ter being mostly extra-nasal and associated with early multifo-
cal distant dissemination.23 The high prevalence of distant failure 
in the present cohort might have been due to subtype heteroge-
neity, as eight of our 55 patients had primary disease in the ex-
tra-nasal area. However, differences in the distant failure rate 
between the two subtypes were not observed (data not shown). 
Seeking a prognostic factor to predict early distant failure is need-
Table 5. Prognostic Factors for OS
Factor 5-yr OS rate p value (univariate)
Age (yrs) 0.5
<54 72%
≥54 61%
Sex 0.9
Male 66%
Female 66%
Primary site (sinonasal vs. others) 0.2
Sinonasal 63%
Other 83%
Ann Arbor stage (I vs. II) 0.5
I 68%
II 60%
Systemic B symptoms 0.7
Yes 66%
No 67%
Epstein-Barr virus 0.37
Yes 79%
No 59%
RT dose 0.3
<50 Gy 63%
≥50 Gy 70%
RT response 0.02
CR 74%
Non CR 42%
Treatment sequence 0.4
RT alone 76%
Upfront CT+RT 69%
CCRT 55%
OS, overall survival; RT, radiotherapy; CR, complete response; CT, chemother-
apy; CCRT, concurrent chemoradiotherapy.
Table 4. Patterns of Failure According to Treatment Modality Groups
Patterns of failure
Treatment groups
p value
RT alone (n=19) CT+RT (n=16) CCRT (n=20)
Local failure 3 (16%) 3 (19%) 1 (5%) 0.361
Regional node failure 1 (5%) 2 (13%) 1 (5%) 0.67
Distant failure 3 (16%) 1 (6%) 5 (25%) 0.345
RT, radiotherapy; CT, chemotherapy; CCRT, concurrent chemoradiotherapy.
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ed for patients who might benefit from the administration of CT.
The present study had several limitations. First, this was an 
institutional-based retrospective study of patients treated with-
out a consistent protocol. There were differences in treatment 
protocols, RT modalities and doses, and CT regimens. However, 
this heterogeneity made it possible to speculate on the role of 
RT and CT for the treatment of early-stage ENKTL. Second, due 
to the rarity of the disease, the number of patients included was 
small, which made it difficult to uncover statistically significant 
prognostic factors. The only significant prognostic factor ap-
peared to be achieving a CR after RT. However, patients classi-
fied as IPI group 3 and NKPI group 4 showed worse OS than 
other groups, although the difference was not significant. There 
were more patients classified as IPI group 3 and NKPI group 4 
in the CCRT group, and this imbalance in patients’ characteris-
tics should be noted.
In conclusion, the outcome of early-stage ENKTL has im-
proved with advances in RT techniques. The local control rate 
in the RT-alone group was similar to that in patients who also 
underwent CT. However, systemic CT did not decrease the dis-
tant failure rate and was associated with considerable toxicities. 
In the era of multimodal treatment for ENKTL, RT alone using 
advanced techniques should be considered for local disease 
control, whereas maintenance treatment containing effective 
CT regimens should be considered for distant disease control.
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